SPRO Earnings & Financial Statements
Spero Therapeutics, Inc.
$1.13
+$0.01(+0.89%)
47
Overall
80
Value
18
Tech
44
Quality
Market Cap
$65.22M
Volume
233.83K
52W Range
$1.08 - $3.08
Target Price
$6.00
SPRO earnings and financial statements: Spero Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
SPRO Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $66.80M | $47.98M | $103.78M | $48.58M | $3.07M |
| Operating income | $6.31M | -$73.36M | $21.48M | -$42.20M | -$87.97M |
| EBITDA | $8.83M | -$68.56M | $25.77M | -$42.94M | -$87.17M |
| Net income | $8.57M | -$68.57M | $22.81M | -$46.41M | -$89.76M |
| EPS (diluted) | $0.15 | $-1.27 | $0.43 | $-1.23 | $-2.91 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $68.92M | $110.54M | $182.39M | $124.80M | $171.07M |
| Total liabilities | $9.90M | $64.42M | $75.50M | $48.87M | $82.78M |
| Shareholders’ equity | $59.02M | $46.12M | $106.89M | $75.93M | $88.29M |
| Cash and equivalents | $40.27M | $52.89M | $76.33M | $109.11M | $112.58M |
| Long-term debt | $1.03M | $2.55M | $3.91M | $5.05M | $6.11M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$12.62M | -$23.44M | -$32.99M | -$7.73M | -$64.35M |
| Free cash flow | -$12.62M | -$23.44M | -$32.99M | -$7.73M | -$64.35M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SPRO | $1.13 | +0.9% | 233.83K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Spero Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW